Recknor would know but last I checked he’s not talking either. Might take more than one drug to right this condition but as we already know, Leronlimab can get you in the red zone for most people. I am a man of science but when people have so lost hope they are killing themselves, as the saying goes “don’t let perfection be the enemy of the good.” IMHO there was a good case for EUA for Leronlimab in longhaulers given no approved therapy for that indication, perfect safety profile and strong study results from early last summer. I wouldn’t care if the study is small, clinical results followed known mechanism of action. Collect additional data based on the law of large numbers with conditional approval, but get some help to people in need don’t put up roadblocks. That said I can’t help but wonder if longhaulers is one more facet of the diamond being evaluated for a different decision, maybe this isn’t the FDA after all.